Conferences

FOIU 2018: Active Surveillance for Intermediate Risk Prostate Cancer - AGAINST

Tel-Aviv, Israel (UroToday.com) Laurence Klotz, MD debated against active surveillance (AS) for intermediate-risk prostate cancer (IRPC). He began with the known data on Gleason grade group 1, and group 2. Gleason score of 3 resembles normal cells in most cases and has a metastatic potential of zero. Conversely, Gleason 4 has a significant metastatic potential. Many Gleason 3+4 cancers are clinically insignificant but some are lethal. The stakes are much higher and the risks much greater.

FOIU 2018: Active Surveillance for Intermediate Risk Prostate Cancer - FOR

Tel-Aviv, Israel (UroToday.com) Larry Goldenberg, MD demonstrated his support for using active surveillance (AS) in intermediate-risk prostate cancer (IRPC). Goldenberg began his talk by stating that not all IRPC is the same. It is agreed by most, that unfavorable IRPC requires treatment.  Conversely, favorable IRPC require more stringent follow-up but deferred therapy is not dangerous. Ultimately, it comes down to a man’s risk threshold (his comfort zone).

FOIU 2018: Can MRI Replace Biopsy in Men on Active Surveillance? - YES

Tel-Aviv, Israel (UroToday.com) Arnauld Villers, MD presented and explained his support of multiparametric MRI (mpMRI) replacing biopsy in men on active surveillance (AS) of prostate cancer (PC). According to the EAU guidelines, there are considerable variations among studies regarding patient selection, follow-up schedule, and the use of confirmatory or repeat biopsy and MRI. 

FOIU 2018: Can MRI Replace Biopsy in Men on Active Surveillance? - NO

Tel-Aviv, Israel (UroToday.com) Reiter presented his view why serial MRI cannot replace biopsy in patients on active surveillance (AS) in prostate cancer (PC) patients. According to Reiter MRI is an excellent (although not perfect) for identification of “significant” tumors”. It has a high negative predictive value (NPV) that aids patient stratification for AS. Therefore, many Gleason grade group 1 (GGG1) tumors are not visible by MRI, and so there is nothing to follow. There is lack of evidence that serial MRI can add to or replace biopsy while on AS.

FOIU 2018: Proper Selection of Patients for Active Surveillance – Primum Non Nocere?

Tel-Aviv, Israel (UroToday.com) Mitchell C. Benson, MD gave a talk on the selection of patients for active surveillance (AS). The Epstein criteria for AS with 95% positive predictive value (PPV) include:

  • Gleason 6 or below 
  • PSA density<0.15
  • <3 cores involved 
  • <50% of any single core involved 

FOIU 2018: Active Surveillance In Young Men

Tel-Aviv, Israel (UroToday.com) Adam Feldman, MD gave a talk on the use of active surveillance (AS) for young patients. AS has become an accepted management strategy for very low risk, low risk, and select favorable intermediate-risk prostate cancer (PC). Although there is a large amount of data supporting AS as a safe strategy, there is a paucity of data in young men.

FOIU 2018: Critical Role of Pathology for Active Surveillance Criteria and Definition of “Progression”

Tel-Aviv, Israel (UroToday.com) Jonathan Epstein, MD, gave an overview of the active surveillance (AS) criteria for prostate cancer (PC), including criteria for selection, follow-up, the trigger for intervention, and change in reporting grade. The criteria for selecting patients for AS are numerous and include:

gucancerssympalt Genitourinary Cancers Symposium 2014

January 30 - February 1, 2014

San Francisco Marriott Marquis
San Francisco, CA USA

24th cap update 24th Int'l. Prostate Cancer Update

February 19 - 22, 2014

Cascade Conference Center
Vail, Colorado USA

sufu x Society of Urodynamics, Female Pelvic Medicine
and Urogenital Reconstruction (SUFU) Winter Meeting

February 25 - March 1, 2014

Doral Golf Resort and Spa
Miami, Florida USA

aua ses78th Annual Meeting of the
Southeastern Section of the AUA
March 20 - 23, 2014

Hollywood, FL USA

eau29th Annual European Association
of Urology (EAU) Congress
April 11 - 15, 2014

Stockholm, Sweden

auaAmerican Urological Association (AUA)
Annual Meeting
May 16 - 21, 2014

Orlando, Florida USA

asco xAmerican Society of Clinical Oncology (ASCO)
2014 Annual Meeting

May 30 - June 3, 2014

McCormick Place
Chicago, IL USA


augs iugaAmerican Urogynecologic Society (AUGS) and
the International Urogynecological Association (IUGA)
Joint Scientific Meetings

July 22 - 26, 2014

Washington, DC USA

32nd World Congress of Endourology & SWLwce

September 3 - 7, 2014

Taipei, Taiwan

2014 Winter Meeting of the Society of Urologic Oncology (SUO)suo

"Defining Excellence in Urologic Oncology"

December 3 - 5, 2014
Bethesda, MD USA

 

 

#SUO14 - Session Highlights: Nerve sparing and template choice

read more

 

#SUO14 - Session Highlights: Choice of templates for low-stage testis cancer

read more

 

#SUO14 - Session Highlights: Minimizing morbidity of RPLND

read more

 

#SUO14 - Session Highlights: The role of SETD2 mutations in the biology of renal cell carcinoma

read more

 

#SUO14 - Session Highlights: Therapy of kidney cancer: Where are we going next?

read more

 

#SUO14 - Session Highlights: Impact of systemic therapy on characterization of peripheral circulating tumor cells in metastatic renal cell carcinoma

read more

 

#SUO14 - Session Highlights: Accelerated growth rate of multifocal tumors after initial radiofrequency ablation

read more

 

#SUO14 - Session Highlights: FSH and the metabolic syndrome

read more

 

#SUO14 - Session Highlights: Non-genomic AR pathway

read more

 

#SUO14 - Session Highlights: What is the impact of ECOG 3805 (CHAARTED) results on clinical practice?

read more

 

#SUO14 - Session Highlights: Sequencing prior to chemotherapy

read more

 

#SUO14 - Session Highlights: Cystectomy enhanced recovery pathway: Reduction in length of stay without increased morbidity or readmission

read more

 

#SUO14 - Session Highlights: Declining rate of prostate biopsy in the Veterans Health Administration in the past decade: An alternate approach to limiting overdiagnosis and overtreatment of prostate cancer?

read more

 

#SUO14 - Session Highlights: Role of 18-FDG PET/CT in staging of penile/urethral squamous cell carcinoma

read more

 

#SUO14 - Session Highlights: Trends in utilization, perioperative outcomes, and costs among open, laparoscopic, and robotic nephroureterectomies: A 10-year population-based analysis

read more

 

#SUO14 - Abstract and Poster: Decline in the use of radiation for stage I seminoma: Analysis of the National Cancer Database

read more

 

#SUO14 - Abstract and Poster: Receipt of inguinal lymph node dissection in patients with T2 penile cancer: Results from the National Cancer Database

read more

 

#SUO14 - Session Highlights: Next generation sequencing of DNA from urine detects multiple bladder tumor-derived alterations and additional changes that suggest tumor heterogeneity

read more

 

#SUO14 - Session Highlights: Is a 12-core biopsy of any value in patients with a previous negative prostate biopsy and visible lesion on magnetic resonance imaging?

read more

 

#SUO14 - Session Highlights: Histology vs. genomics: Does Gleason 3 have the hallmarks of cancer?

read more

 

#SUO14 - Session Highlights: Should MR be the standard of care before biopsy?

read more

 

#SUO14 - Session Highlights: Imaging for biochemical recurrence

read more

 

#SUO14 - Session Highlights: Long-term adverse effects in testicular cancer survivors

read more

 

#SUO14 - Session Highlights: What a urologist should do based upon long-term side effects of chemotherapy

read more

 

#SUO14 - Session Highlights: New approaches to chemotherapy in bladder cancer

read more

 

#SUO14 - Session Highlights: Management of locally advanced renal cell carcinoma and management of the adrenal gland

read more

 

#SUO14 - Session Highlights: Role of lymph node dissection in advanced RCC

read more

 

#SUO14 - Session Highlights: Management of IVC thrombi

read more

 

#SUO14 - Session Highlights: Checkpoint targeted immunotherapy

read more

 

#SUO14 - Session Highlights: The role of neoadjuvant therapy in kidney cancer patients

read more

 

#SUO14 - Session Highlights: Role of surgery for nodal oligometastatic disease in men with biochemical failure

read more

 

#SUO14 - Session Highlights: Role of post-op RT for pN+ after prostatectomy

read more

 

#SUO14 - Session Highlights: Radical prostatectomy for oligometastatic disease

read more

 

#SUO14 - Session Highlights: Targeting hormone-DNA repair crosstalk in prostate cancer: Implications for disease progression and therapeutic intervention

read more

 

#SUO14 - Session Highlights: Targeting PD-1 and PD-L1 in bladder cancer 

read more

 

#SUO14 - Session Highlights: Clinical trials of novel targeted agents

read more

 

#SUO14 - Abstract and Poster: Neoadjuvant chemotherapy is not associated with increased risk of perioperative complications, mortality, nor readmission rates in patients undergoing radical cystectomy

read more

 

#SUO14 - Abstract and Poster: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

read more

 

#SUO14 - Session Highlights: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

read more

 

#SUO14 - Abstract and Poster: Surgical Apgar score predicts an increased risk for death and readmission following radical cystectomy

read more

 

#SUO14 - Abstract and Poster: Surgical Apgar score and nephrometry score predict increased risk for major complication and death following renal mass excision

read more

 

#SUO14 - Session Highlights: New insights into bladder cancer subtyping

read more

 

#SUO14 - Session Highlights: Genetic findings in invasive bladder cancer: Recent Data and clinical implications

read more

 

#SUO14 - Session Highlights: Epigenetic control of bladder cancer heterogeneity by non-coding RNAs

read more

 

#SUO14 - Session Highlights: Towards a molecular genetic and functional classification of renal cancer

read more

 

#SUO14 - Session Highlights: Biology of bladder cancer metastasis

read more

 

#SUO14 - Session Highlights: Challenges and opportunities facing tumor and therapeutic heterogeneity of kidney cancer

read more

 

#SUO14 - Session Highlights: RCC tumor ontogeny – lessons from the small renal mass

read more

 

#SUO14 - Session Highlights: Optimal targeting of the PD-1/PDL-1 pathway in metastatic renal cell carcinoma

read more

 

gucancerssympalt Genitourinary Cancers Symposium 2015

February 26 - 28, 2015

Rosen Shingle Creek
Orlando, FL USA

 

 

 #GU15 - Androgen deprivation therapy, cardiovascular risk, and multidisciplinary management of the prostate cancer patient: A German perspective - Session Highlights

read more

 

#GU15 - AR splice variant 7 (AR-V7) could be a marker for treatment selection in metastatic castrate-resistant prostate cancer

read more

 

#GU15 - Novel imaging modalities boost detection of early metastatic disease in prostate cancer - Session Highlights

read more

 

#GU15 - Progress and challenges in penile, urethral, and testicular cancer - Session Highlights

read more

 

#GU15 - Prostate cancer in 2014- 2015: Advances and ongoing challenges in therapeutics, biomarkers, and precision medicine

read more

 

#GU15 - Renal cell cancer keynote: Management of RCC: Future needs and opportunities - Session Highlights

read more

 

#GU15 - Year in review: Renal cell cancer - Session Highlights

read more

 

#GU15 - Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial - Session Highlights

read more

 

#GU15 - Metabolic pathways - Session Highlights

read more

 

#GU15 - Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma - Session Highlights

read more

 

#GU15 - Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience - Session Highlights

read more

 

#GU15 - Correlation of baseline serum testosterone and PSA at 7 months in patients with new metastatic prostate cancer treated with continuous ADT - Session Highlights

read more

 

#GU15 - Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets - Session Highlights

read more

 

#GU15 - AR modulation optimized for response in splice variant (ARMPR3-SV): A RCT of galeterone vs enzalutamide in men expressing ARv7 in mCRPC - Session Highlights

read more

 

#GU15 - Poster: Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup

read more

 

#GU15 - Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup - Session Highlights

read more

 

#GU15 - Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting - Session Highlights

read more

 

#GU15 - Radium-223 dichloride (Ra-223) in U.S. Expanded Access Program (EAP) - Session Highlights

read more

 

#GU15 - Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel - Session Highlights

read more

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

read more

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

read more

 

#GU15 - Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone - Session Highlights

read more

 

#GU15 - Urothelial carcinoma keynote - Session Highlights

read more

 

#GU15 - Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer - Session Highlights

read more

 

#GU15 - The impact of time to metastasis on survival in treatment-naïve prostate cancer patients - Session Highlights

read more

 

#GU15 - A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study - Session Highlights

read more

 

#GU15 - Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety - Session Highlights

read more

 

#GU15 - Best of journals: mCRPC treatment - Session Highlights

read more

 

#GU15 - Urothelial carcinoma: Year in review - Session Highlights

read more

 

#GU15 - The biology of bladder cancer metastasis - Session Highlights

read more

 

#GU15 - What is new in systemic therapy for urothelial tumors? - Session Highlights

read more

 

#GU15 - Best of journals: Prostate cancer - Session Highlights

read more

 

#GU15 - Best of journals - Session Highlights

read more

 

#GU15 - Dynamic changes in biomarkers for immune response to sipuleucel-T for mCRPC - Session Highlights

read more

 

#GU15 - FANCA loss as a biomarker of platinum sensitivity in prostate cancer - Session Highlights/span>

read more

 

#GU15 - Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014 - Session Highlights

read more

 

#GU15 - Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? - Session Highlights

read more

 

#GU15 - Testosterone levels in metastatic castration resistant prostate cancer (mCRPC) - Session Highlights

read more

 

#GU15 - Poster: 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA

read more

  

#GU15 - 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA - Session Highlights

read more

 

#GU15 - Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial - Session Highlights

read more

 

#GU15 - Prostate Cancer Keynote: Can epigenetic alterations in human cancers be exploited for cancer screening, detection, diagnosis and treatment? - Session Highlights

read more

 

#GU15 - Prostate cancer: Year in review - Session Highlights

read more

 

#GU15 - ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer - Session Highlights

read more

 

#GU15 - ADT plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial - Session Highlights

read more

 

#GU15 - Characterization of abiraterone responses in African American men with castrate resistant prostate cancer - Session Highlights

read more

 

#GU15 - Effects of radium-223 dichloride with docetaxel (D) versus D on PSA and bone alkaline phosphatase in patients with castration-resistant prostate cancer and bone metastases: A phase 1/2a clinical trial - Session Highlights

read more

 

#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302

read more

 

#GU15 - Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 - Session Highlights

read more

 

#GU15 - Poster: External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

read more

 

#GU15 - External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial - Session Highlights

read more

 

#GU15 - Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT - Session Highlights

read more

 

#GU15 - AR-based biomarker association with response to abiraterone in mCRPC - Session Highlights

read more

 

#GU15 - Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer - Session Highlights

read more

 

#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights

read more

 

#GU15 - Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial - Session Highlights

read more

 

#GU15 - Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF) - Session Highlights

read more

 

#GU15 - Early radiation response between GnRH agonist versus antagonist combined with radiotherapy in high-risk prostate cancer - Session Highlights

read more

 

#GU15 - Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients - Session Highlights

read more

 

#GU15 - Abstract highlights: AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC - Session Highlights

read more

 

#GU15 - Bench to bedside: Androgen resistance - Session Highlights

read more

 

#GU15 - Clinical context: Using new imaging modalities to identify early metastatic disease - Session Highlights

read more

 

#GU15 - Role of local therapy - Session Highlights

read more

 

#GU15 - A multi-institutional prospective trial in the United States confirms the 4K Score accurately identifies men with high-grade prostate cancer - Session Highlights

read more

 

#GU15 - Biomarkers for prostate cancer: Why aren’t we using them and where do we go from here? - Session Highlights

read more

 

#GU15 - Hormonal therapy: How long is enough? - Session Highlights

read more

 

#GU15 - Who can receive shorter-course radiotherapy? Hypofractionation and stereotactic body radiation therapy - Session Highlights

read more

 

#GU15 - Individualized treatment decisions for localized prostate cancer: Decision aids and quality of life outcomes - Session Highlights

read more

 

Bayer presents latest oncology research at ASCO GU 2015

read more

 

Early evidence of increase in higher-risk prostate cancers from 2011-2013

read more

 

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

read more

 

Men who have had testicular cancer are more likely to develop prostate cancer, although overall risk of developing aggressive disease is low

read more

 

 

Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

read more

 

 

Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

read more

 

 

 

auaAmerican Urological Association (AUA)
Annual Meeting
May 15 - 19, 2015

New Orleans, Louisiana USA



asco xAmerican Society of Clinical Oncology (ASCO)
2015 Annual Meeting

May 29 - June 2, 2015

McCormick Place
Chicago, IL USA


Winter Meeting of the Society of Urologic Oncology (SUO)suo

"Defining Excellence in Urologic Oncology"

December 2 - 4, 2015
Washington, DC USA